MoonLake Immunotherapeutics reported Phase 2 results showing its investigational drug produced clinically meaningful benefit in patients with an aggressive inflammatory arthritis subtype, a company source told Endpoints. MoonLake said it has confidence as it prepares an impending FDA submission. The data reportedly supported improvement on key clinical endpoints versus baseline and informed MoonLake’s regulatory strategy. The asset’s Phase 2 signal will determine the scale and timing of a pivotal program; the company’s next steps include finalizing submission materials and engaging with regulatory authorities on trial design and labeling.